期刊文献+

罕见病医疗保障的国际比较研究 被引量:23

International Comparative Study about Rare Diseases' Medicare
下载PDF
导出
摘要 罕见病医疗保障已经得到各国和地区的关注,并在实践中不断探索与完善。本文简述了罕见病的特征,并分析了罕见病患者所处的困境,提出罕见病立法和医疗保障政策制定的重要性和紧迫性。同时,通过介绍和总结美国、欧盟、日本、中国台湾地区等在罕见病的立法与医疗保障方面的具体做法和经验,为我国制定罕见病的相关政策、建立罕见病患者的医疗费用负担机制提供了思路和依据。 Rare diseases' medicare has received concern in many countries and regions, and it has gotten continuous exploration and improvement in practice. This article described the characteristics of rare diseases, and discussed the problems presented in rare diseases' medicare, which implied the importance and urgency of establishment about rare diseases' legislation and medicare policy. Meanwhile, the article also described and analyzed the current situation about rare diseases' legislation and medicare policy in other countries and regions, including the United States, European Union, Japan, Taiwan. The experiences and policies in these countries or regions will be helpful and provide ideas for the establishment of related policies about rare diseases and mechanisms for medical expenses in China.
出处 《药品评价》 CAS 2014年第6期8-11,共4页 Drug Evaluation
关键词 罕见病 罕用药 立法 医疗保障 Rare Diseases Orphan Drugs Legislation Medicare
  • 相关文献

参考文献8

  • 1European Council. Council Recommendation of 8 June 2009 on European Action in the Field of Rare Diseases[J]. Official Journal of the European Union, 2009, C151: 7-10.
  • 2Eurordis. Eurordis Care 2: Survey of Diagnostic Delays, 8 Diseases, Europe[OL]. 2004. http://archive.eurordis.org/article.php3?id article=454.
  • 3Thamer M, Brennan N, Semansky R. A Cross-National Comparison of Orphan Drug Policies: Implications for the U.S. Orphan Drug Act[J]. Journal of Health Politics, Policy and Law, 1998, 23: 265-290.
  • 4Makoto S, Kiyohito N. Development of Orphan Drugs in Japan: Characteristics of Orphan Drugs Developed in Japan[J]. Drug Information Journal, 2000, 34: 839-846.
  • 5Makoto S, Kiyohito N. Development of Orphan Drugs in Japan: Effects of A Support System for Development of Orphan Drugs in Japan[J]. Drug Information Journal, 2000, 34: 829-837.
  • 6Shulman, SR, Manocchia, M. The US Orphan Drug Programme 1983-1995[J]. Pharmaco- Economics, 1997, 12: 312-326.
  • 7Shiragami M. Forefront of Orphan Drugs-Overview of Orphan Drugs Development Supporting System[J]. Dispensing Drug lnf, 1999, 5: 7.
  • 8National PKU News[OL].2001. http://www.pkunews.org.

同被引文献232

引证文献23

二级引证文献156

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部